Loading
Every dated change on the records linked to HER2-positive breast cancer with brain metastases, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Neratinib plus capecitabine improved progression-free survival over lapatinib plus capecitabine and reduced interventions for central nervous system disease; approved in February 2020.
A milestone in how this cancer is treated.
Cognitive deterioration at 3 months 63.
A milestone in how this cancer is treated.